Drug Information
| Drug General Information | |||||
|---|---|---|---|---|---|
| Drug ID |
D0NS8T
|
||||
| Former ID |
DIB009018
|
||||
| Drug Name |
13-DEOXYADRIAMYCIN HYDROCHLORIDE
|
||||
| Synonyms |
GPX-100; (8R,10S)-10-(3-Amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranosyloxy)-7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(2-hydroxyethyl)-1-methoxynaphthacene-5,12-dione hydrochloride; 13-Deoxydoxorubicin hydrochloride
|
||||
| Indication | Solid tumours [ICD9: 140-199, 210-229; ICD10:C00-D48] | Phase 2 | [1] | ||
| Company |
Access Pharmaceuticals
|
||||
| Structure |
|
Download2D MOL |
|||
| Target and Pathway | |||||
| Target(s) | Human DNA | Target Info | Modulator | [2] | |
| DNA topoisomerase II | Target Info | Modulator | [2] | ||
| References | |||||
| REF 1 | ClinicalTrials.gov (NCT00123877) Study of GPX-100 in the Treatment of Metastatic Breast Cancer. U.S. National Institutes of Health. | ||||
| REF 2 | Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41. | ||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.